Erdafitinibin intravesikaalinen annostelujärjestelmä paikallisen virtsarakon syövän hoidossa
Vaiheen 1 tutkimus erdafitinibin intravesikaalisesta annostelujärjestelmästä (TAR-210) osallistujilla, joilla on ei-lihakseen invasiivinen tai lihakseen invasiivinen virtsarakon syöpä ja valikoituja FGFR-mutaatioita tai -fuusioita
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Bladder cancer is one of the most common malignancy worldwide, and non-muscle invasive (NMIBC) requires intensive regimens of frequent monitoring and local resection (transurethral resection of bladder [TURBT]). This study enrolls participants with non-muscle invasive or muscle invasive bladder cancer with activating fibroblast growth factor receptor (FGFR) mutations or fusions. Erdafitinib is a pan-FGFR inhibitor with demonstrated clinical activity when administered orally in patients with solid tumors, including bladder cancer, with FGFR genetic alterations. The Erdafitinib intravesical delivery system is designed to provide release of Erdafitinib in the bladder to treat localized bladder cancer, while reducing systemic toxicities. The study consists of a screening phase, a treatment phase, and a follow-up phase. Total duration of the study is approximately up to 7 years 4 months.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Nijmegen, Alankomaat, 6525 GA
- Radboud Umcn
-
Utrecht, Alankomaat, 3584 CX
- UMC Utrecht
-
-
-
-
-
Barcelona, Espanja, 08025
- Fund. Puigvert
-
Barcelona, Espanja, 08036
- Hosp Clinic de Barcelona
-
Barcelona, Espanja, 08035
- Hosp Univ Vall D Hebron
-
Córdoba, Espanja, 14004
- Hosp Reina Sofia
-
Madrid, Espanja, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Espanja, 28046
- Hosp. Univ. La Paz
-
Madrid, Espanja, 28040
- Hosp Univ Fund Jimenez Diaz
-
Valencia, Espanja, 46009
- Instituto Valenciano de Oncologia
-
-
-
-
-
Goyang-si, Etelä -Korea, 10408
- National Cancer Center
-
Gwangju, Etelä -Korea, 61469
- Chonnam National University Hospital
-
Seoul, Etelä -Korea, 03080
- Seoul National University Hospital
-
Seoul, Etelä -Korea, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Etelä -Korea, 06591
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Haifa, Israel, 3109601
- Rambam Medical Center
-
Haifa, Israel, 3436212
- Carmel Medical Center
-
Petah Tikva, Israel, 4941492
- Rabin Medical Center
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Fukuoka, Japani, 810 8563
- National Hospital Organization Kyushu Medical Center
-
Kofu, Japani, 400-8506
- Yamanashi Prefectural Central Hospital
-
Osaka, Japani, 558-8558
- Osaka General Medical Center
-
Toyama, Japani, 930 0194
- Toyama University Hospital
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Vancouver Prostate Centre Diamond Health Care Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 2Y9
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 4A6
- St Josephs Healthcare Hamilton
-
Toronto, Ontario, Kanada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
Dresden, Saksa, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Duisburg, Saksa, 47169
- Urologicum Duisburg
-
Frankfurt am Main, Saksa, 60590
- Universitatsklinikum Frankfurt
-
Herne, Saksa, 44625
- Marien hospital Herne
-
Mettmann, Saksa, 40822
- Urologie Neandertal Praxis Mettmann
-
Münster, Saksa, 48149
- Universitatsklinikum Munster
-
Ulm, Saksa, 89081
- Universitaetsklinikum Ulm
-
-
-
-
Alabama
-
Birmingham, Alabama, Yhdysvallat, 35294
- University of Alabama at Birmingham - The Kirklin Clinic
-
-
California
-
Los Angeles, California, Yhdysvallat, 90033
- University of Southern California
-
-
Colorado
-
Lone Tree, Colorado, Yhdysvallat, 80124
- Urology Associates of Denver
-
-
Florida
-
Hialeah, Florida, Yhdysvallat, 33016
- Urological Research Network
-
Largo, Florida, Yhdysvallat, 33771
- Advanced Urology Institute
-
Orlando, Florida, Yhdysvallat, 32804
- Advent Health Orlando
-
Oxford, Florida, Yhdysvallat, 34484
- Advanced Urology Institute 1
-
Tampa, Florida, Yhdysvallat, 33612
- H Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Northwestern University
-
Chicago Ridge, Illinois, Yhdysvallat, 60415
- Associated Urological Specialists
-
-
Indiana
-
Greenwood, Indiana, Yhdysvallat, 46143
- Urology of Indiana
-
Merrillville, Indiana, Yhdysvallat, 46410
- Urologic Specialists of Northwest Indiana
-
-
Kentucky
-
Lexington, Kentucky, Yhdysvallat, 40506
- University of Kentucky
-
-
Louisiana
-
Lafayette, Louisiana, Yhdysvallat, 70508
- Southern Urology LLC
-
-
Massachusetts
-
Plymouth, Massachusetts, Yhdysvallat, 02360
- Greater Boston Urology
-
-
Missouri
-
St Louis, Missouri, Yhdysvallat, 63141
- Specialty Clinical Research of St Louis
-
-
New Jersey
-
Hackensack, New Jersey, Yhdysvallat, 07601
- Hackensack University Medical Center Urology
-
-
New York
-
Syracuse, New York, Yhdysvallat, 13210
- Associated Medical Professionals
-
-
North Carolina
-
Charlotte, North Carolina, Yhdysvallat, 28204
- Levine Cancer Institute, Carolinas HealthCare System
-
-
Ohio
-
Gahanna, Ohio, Yhdysvallat, 43230
- Central Ohio Urology Group
-
-
South Carolina
-
Myrtle Beach, South Carolina, Yhdysvallat, 29572
- Carolina Urologic Research Center
-
North Charleston, South Carolina, Yhdysvallat, 29406
- Low Country Urology Clinics
-
-
Tennessee
-
Nashville, Tennessee, Yhdysvallat, 37209
- Urology Associates
-
-
Texas
-
Austin, Texas, Yhdysvallat, 78745
- Urology Austin
-
San Antonio, Texas, Yhdysvallat, 78229
- Urology San Antonio Research
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Parts 1-3:
- Muscle-invasive or recurrent, non-muscle-invasive urothelial carcinoma of the bladder
- For selected Cohorts: Activating tumor pan-fibroblast growth factor receptor (FGFR) mutation or fusion, as determined by local or central testing, approved by the sponsor prior to the start of study treatment. Local tissue-based results (if already existing) from next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests performed in Clinical Laboratory Improvement Amendments (CLIA) -certified or equivalent laboratories, or results from commercially available PCR or NGS tests
- Cohorts 1 and 2: Bacillus Calmette-Guérin (BCG) experienced, or participants with no BCG experience because BCG was not available as a treatment option in the participant's location within the previous 2 years and is currently unavailable. Participants who received an abbreviated course of BCG due to toxicity are still eligible
- Cohort 1 only: Refuses or is not eligible for radical cystectomy (RC)
- Cohorts 2 and 4: Willing and eligible for RC
Part 4:
- Have histologically confirmed diagnosis of recurrent Intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC) Ta LG tumors
- Must not have undergone tumor debulking or selective ablation of visible lesions; partial tumor biopsy to confirm diagnosis and provide tissue for biomarker testing is permitted as long as remaining tumor is at least 5 millimeter (mm) in size
- Must submit tissue and urine for FGFR testing
- Can have a prior or concurrent second malignancy which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
Exclusion Criteria:
Parts 1-3:
- Concurrent extra-vesical (that is, urethra, ureter, renal pelvis) transitional cell carcinoma of the urothelium
- Prior treatment with an pan-fibroblast growth factor receptor (FGFR) inhibitor
- Received pelvic radiotherapy <=6 months prior to the planned start of study treatment. If received pelvic radiotherapy greater than (>)6 months prior to the start of study treatment, there must be no cystoscopic evidence of radiation cystitis
- Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe use of Erdafitinib intravesical delivery system
- Indwelling urinary catheter. Intermittent catheterization is acceptable
Part 4:
- Histologically confirmed diagnosis of T1 NMIBC, HR NMIBC (HG/G2 or HG/G3 or CIS) or MIBC, locally advanced, non-resectable, or metastatic urothelial carcinoma at any time prior to enrollment. Previous high grade (HG) disease is accepted as long as diagnosis date is greater than or equal to (>=5) years ago and there is documentation of low grade (LG) Ta thereafter
- Known allergies, hypersensitivity, or intolerance to any study component or its excipients
- Has a current diagnosis of newly diagnosed IR-NMIBC
- Received an investigational treatment for bladder cancer after Transurethral Resection of the Bladder Tumor (TURBT) for the current NMIBC diagnosis or within 4 weeks or the agent/therapy washout period, whichever is longer, before the planned first dose of study treatment, or is currently enrolled in an investigational study
- Evidence of current bladder perforation by cystoscopy or imaging
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part 1: Dose Escalation
Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D[s]) for Part 2. |
Erdafitinib intravesical delivery system will be administered.
Muut nimet:
|
|
Kokeellinen: Part 2: Dose Expansion
Participants in each of 5 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1. |
Erdafitinib intravesical delivery system will be administered.
Muut nimet:
|
|
Kokeellinen: Part 3: RP2D Dose Expansion
Participants in 2 of the disease-specific NMIBC cohorts (cohorts 1 and 3) may be enrolled at RP2D to determine the safety, evaluate PK and preliminary clinical activity. |
Erdafitinib intravesical delivery system will be administered.
Muut nimet:
|
|
Kokeellinen: Part 4: Phase 2 Expansion
Participants with recurrent IR-NMIBC will be enrolled in this part to further evaluate the safety, efficacy, and PK of the selected RP2D. |
Erdafitinib intravesical delivery system will be administered.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Parts 1 to 3: Number of Participants with Adverse Events (AEs)
Aikaikkuna: Up to approximately 7 years 4 months
|
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. |
Up to approximately 7 years 4 months
|
|
Parts 1 to 3: Number of Participants with AEs by Severity
Aikaikkuna: Up to approximately 7 years 4 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 7 years 4 months
|
|
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
Aikaikkuna: Up to 28 days
|
Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 28 days
|
|
Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)
Aikaikkuna: Up to approximately 7 years 4 months
|
Overall CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy. |
Up to approximately 7 years 4 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Parts 1 to 3: Plasma Concentration of Erdafitinib
Aikaikkuna: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
Plasma concentration of Erdafitinib will be reported. |
Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
|
Parts 1 to 3: Urine Concentration of Erdafitinib
Aikaikkuna: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
Urine concentration of Erdafitinib will be reported. |
Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
|
Parts 1 to 3: Cohorts 1 and 2: Recurrence-Free Survival (RFS)
Aikaikkuna: Up to approximately 7 years 4 months
|
RFS is defined as the time from start of treatment to the first detection of any new high-grade bladder cancer or upper tract urothelial carcinoma or positive urine cytology. |
Up to approximately 7 years 4 months
|
|
Parts 1 to 3: Cohort 3 and 5: Complete Response (CR) Rate
Aikaikkuna: At 3 months
|
CR is defined as the absence of urothelial carcinoma by cystoscopy, confirmed pathologically at first assessment, and negative urine cytology. |
At 3 months
|
|
Parts 1 to 3: Cohort 3 and 5: Duration of CR
Aikaikkuna: Up to approximately 7 years 4 months
|
Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first. |
Up to approximately 7 years 4 months
|
|
Parts 1 to 3: Cohort 4: Pathological Complete Response (pCR) Rate
Aikaikkuna: Up to 8 weeks
|
pCR rate is defined as percentage of participants with no pathologic evidence of intravesical disease (pT0) and no pathologic evidence of nodal involvement (pN0). |
Up to 8 weeks
|
|
Parts 1 to 3: Cohort 4: No Pathologic Evidence of Intravesical Disease (pT0)
Aikaikkuna: Up to 8 weeks
|
pT0 rate is defined as percentage of participants with no Pathologic Evidence of Intravesical Disease. |
Up to 8 weeks
|
|
Parts 1 to 3: Cohort 4: Rate of downstaging to Less than (<) pT2
Aikaikkuna: Up to 8 weeks
|
Rate of downstaging to <pT2 is defined as percentage of participants with pT stage <2. |
Up to 8 weeks
|
|
Part 4: Duration of CR (DoCR) in Participants with IR-NMIBC
Aikaikkuna: Up to approximately 7 years 4 months
|
Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first. |
Up to approximately 7 years 4 months
|
|
Part 4: Complete Response (CR) at 3 Months in Participants with IR-NMIBC
Aikaikkuna: At Month 3
|
CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy at the first disease evaluation. |
At Month 3
|
|
Part 4: Transurethral Resection of the Bladder Tumor (TURBT)-Free Survival in Participants With IR-NMIBC
Aikaikkuna: Up to approximately 7 years 4 months
|
Participants with TURBT-free survival will be reported. |
Up to approximately 7 years 4 months
|
|
Part 4: Number of Participants with Treatment-Emergent Adverse Event (TEAEs) by Severity
Aikaikkuna: Up to approximately 7 years 4 months
|
TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline. Severity was assessed using National cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity grades ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 7 years 4 months
|
|
Part 4: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) Score
Aikaikkuna: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
|
Part 4: Change from Baseline in European Organization for the Research and Treatment of Cancer Non-Muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC 24) Score
Aikaikkuna: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
|
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-C30 Scores
Aikaikkuna: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
|
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-NMIBC24 Scores
Aikaikkuna: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Neoplasmat
- Miesten urogenitaaliset sairaudet
- Urologiset sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Neoplasmat histologisen tyypin mukaan
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Urologiset kasvaimet
- Karsinooma
- Virtsarakon sairaudet
- Virtsarakon kasvaimet
- Ei-lihakseen invasiiviset virtsarakon kasvaimet
- erdafitinibi
Muut tutkimustunnusnumerot
- CR109115
- 42756493BLC1003 (Muu tunniste: Janssen Research & Development, LLC)
- 2021-004144-22 (EudraCT-numero)
- 2023-506265-65-00 (Rekisterin tunniste: EUCT number)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .